makinezmoney
2 years ago
$HYEX: Great Quarterly Earnings report.... Revs up 187%
Very nice
Now at 0.055
Healthy Extracts Expects Q1 2022 Net Revenue up 187% to Record $489,000, Driving First Profitable Quarter
April 12, 2022 08:31 ET | Source: Healthy Extracts Inc.
...
LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported preliminary unaudited results for the first quarter ended March 31, 2022.
Net revenue for the first quarter is expected to total more than $489,000, up 187% over the same year-ago quarter, and keeps full year outlook on track for revenue to double to more than $3 million.
βOur record top-line for a first quarter resulted primarily from expansion of direct-to-consumer channels, including a four-fold increase in recurring revenue from product subscriptions,β stated Duke Pitts, president of Healthy Extracts. βWe also expect this strong performance to drive our first-ever positive net income quarter.β
Over the past year, the company established a solid foundation for addressing the fast-growing brain and heart health supplement market, including key acquisitions and successful clinical studies that support its productsβ health benefit claims.
βWe believe the progress we have made, particularly with expanding our sales channels and portfolio of clinically proven natural products, keeps us on course for our earlier guided 100% sales growth in 2022,β added Duke. βTogether with our continued focus on building our recurring revenue stream from subscriptions, we anticipate a continued strengthening of our shareholder value throughout the year.β
The preliminary unaudited results are estimates only and are subject to revision until the company reports its financial results for the first quarter ended March 31, 2022, which it expects to report in May.
About Healthy Extracts βLive Life Young Againβ
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.
The companyβs subsidiaries, BergametNAβ’ and Ultimate Brain Nutrientsβ’ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruitβ’. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more than 17 clinical studies.
UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2022, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food and Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctorβs advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNAβ’, Ultimate Brain Nutrientsβ’, UBNβ’, Citrus Bergamot SuperFruitβ’ and F4T® are registered trademarks of Healthy Extracts Inc.β’
Healthy Extracts Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact:
Ronald Both or Justin Lumley
CMA
Tel (949) 432-7566
Email contact
Media Contact:
Tim Randall
CMA
Tel (949) 432-7572
Email contact
GO $HYEX
yankee2
3 years ago
HYEX .07 chreap imo
https://healthyextractsinc.com/
Key 2020 Activities:
Gross revenue was up 71% in 2020, even with some continued negative effects of COVID.
Healthy Extracts Inc. (HYEX) name change from Grey Cloak Tech to better align its companies.
Full reporting and upgraded to the OTCQB in October 2020.
Independent report conducted by Trickle Research projecting positive stock growth.
Company eliminated all convertible debt.
Net shareholder equity increase of $3.7 million.
Acquired Ultimate Brain Nutrients for its breakthrough brain products, including six patents (2 issued, 4 pending) and its proprietary formulations.
Introduction of the revolutionary Clinical Immune, the only immune product formulated and clinically proven focusing on heart and respiratory immune health.
Key clinical studies on its proprietary unique Fuel4Thought Brain Booster product, with sales beginning in Q2.
Pilot study completed on the Companyβs Fuel4Thought Migraine formulation with great results; study was published in the renowned World Journal of Advanced Research and Reviews.
Release of HerHeart, the only cardiovascular product designed just for women; positive clinical trial results published in Annals of Women's Health. Cardiovascular disease is and will likely remain the No. 1 cause of death in the U.S. for women and men.